Junge, Candice

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Mummery, C. J., Börjesson-Hanson, A., Blackburn, D. J., Vijverberg, E. G. B., De Deyn, P. P., Ducharme, S., Jonsson, M., Schneider, A., Rinne, J. O., Ludolph, A. C., et al. (2023) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 347

Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease: A Randomized Clinical Trial

Edwards, A. L., Collins, J. A., Junge, C., Kordasiewicz, H., Mignon, L., Wu, S., Li, Y., Lin, L., DuBois, J., Hutchison, R. M., et al. (2023) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 113

Results of the first-in-human, randomized, double-blind, placebo-controlled phase 1b study of lumbar intrathecal bolus administrations of antisense oligonucleotide (ISIS 814907; BIIB080) targeting tau mRNA in patients with mild Alzheimer's disease

Mummery, C. J., Junge, C., Kordasiewicz, H. B., Mignon, L., Moore, K. M., Yun, C., Baumann, T. L., Li, D., Norris, D. A., Crean, R., et al. (2021) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 16

Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease

Shulman, M., Wu, S., Ziogas, N., Edwards, A., Collins, J., Lin, L., Tien, I., Curiale, G., Li, Y., Mummery, C., et al. (2026) · Nature Aging

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 11